mylan

What is going on with this division ? Respiratory seems to be the end all be all.. BTW..I’m asking for a friend…

Mylan N.V. (MYL) reported its financial results for the quarter ended March 31, 2020, on Monday before the market opens. The company reaffirmed its financial guidance for the full-year 2020. The results were driven by overall volume growth, which was favorably impacted by increased customer...

If you're considering joining Mylan's Women's Health division, you may want to ask why approximately 15 people have left since it began last year.

If you're considering working in Mylan's Women's Health division, you may want to ask why there is such a high turnover rate. At least 15 people have left, either voluntarily or involuntarily in the past year.

Teva pharma receives a booster shot with FDA's approval for its generic version of EpiPen and EpiPen Jr. This will be a real threat to Mylan. Also, Teva and Regeneron announce positive Phase 3 Fasinumab results in patients with chronic pain from osteoarthritis...

Teva pharma receives a booster shot with FDA's approval for its generic version of EpiPen and EpiPen Jr. This will end the monopoly of Mylan. Also, Teva and Regeneron announce positive Phase 3 Fasinumab results in patients with chronic pain from osteoarthritis...

Amgen (AMGN) announced positive top-line results from the phase 3 trial of its biosimilar candidate ABP 710. The drug is a biosimilar of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade (infliximab). If the drug succeeds, Amgen is well positioned to be a key player in the...

Mylan gets FDA approval for its first biosimilar infection-fighting treatment Neulasta manufactured by Amgen. Mylan plans for the first launch of its biosim Fulphila in a few weeks, with an aim of offering an inexpensive treatment for cancer patients...

Mylan’s billion dollar emergency allergy treatment injector EpiPen is now being added to the list of medications in short supply by the U.S. Food and Drug Administrations, after several consumers in the U.S. with allergies found it difficult to find Mylan’s allergy device...

Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters. The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in...

After weeks of offers and speculations, a deal has finally been struck in the consumer health space, though not really in an expected manner. P&G has ditched Pfizer’s consumer health unit to buy the same business of rival Merck, which was eyed by Mylan NV. P&G was willing to pay $15 billion for...

I'm considering an offer for a finance job at Mylan HQ in SouthPointe. Any advice on what culture andwork life balance are like in this part of the company? Thanks.

Both Pfizer and Merck planned to dispose their consumer health businesses since they failed to return profits, dampening their efforts to innovate in other segments. However, bidders eventually lost interest in Merck’s consumer health line, even as the auction of Pfizer’s consumer health unit...

There is a lot to look forward to as Mylan reports earnings aftermarket today. The stock has been up 9.65% since it reported last quarter results. Market pundits expect earnings to be lower this quarter, complemented by a sales decline of 0.80%...

When is this Teva epipen thing coming out? I asked the doctor but he hasn't heard anything about it from his Teva rep yet, so I guess the reps aren't shoving it in his face like Mylan. I saw that its been failing all sorts of things with the FDA but may finally be ok? Any chance there will...

Texas court says Allergan's Mohawk Tribe patent deal is invalid. Earlier, Mylan had fired back at rival Allergan's attempt to shield its patent for Restasis.